Log in

OTCMKTS:CYYNF - Cynata Therapeutics Stock Price, Forecast & News

0.00 (0.00 %)
(As of 12/4/2019)
Today's Range
Now: $0.72
50-Day Range
MA: $0.81
52-Week Range
Now: $0.72
Volume2,500 shs
Average Volume125 shs
Market Capitalization$65.39 million
P/E RatioN/A
Dividend YieldN/A
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand name for human therapeutic use in Australia. Its lead therapeutic product candidate is CYP-001, which is in Phase I clinical trial for the treatment of graft versus host disease. The company also develops products for the treatment of heart attack, asthma, acute respiratory distress syndrome, diabetic wounds, coronary artery disease, brain cancer, and critical limb ischaemia, which are in preclinical model. The company has a partnership with Monash University, Critical Care Research Group, University of Sydney, Department of Neurosurgery at Brigham and Women's Hospital - Harvard Medical School, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, and the Royal College of Surgeons Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.

Industry, Sector and Symbol

Industry Sanitary paper products



Sales & Book Value

Annual SalesN/A



Market Cap$65.39 million
Next Earnings DateN/A
OptionableNot Optionable

Receive CYYNF News and Ratings via Email

Sign-up to receive the latest news and ratings for CYYNF and its competitors with MarketBeat's FREE daily newsletter.

Cynata Therapeutics (OTCMKTS:CYYNF) Frequently Asked Questions

What is Cynata Therapeutics' stock symbol?

Cynata Therapeutics trades on the OTCMKTS under the ticker symbol "CYYNF."

What is the consensus analysts' recommendation for Cynata Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cynata Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cynata Therapeutics.

Has Cynata Therapeutics been receiving favorable news coverage?

Media headlines about CYYNF stock have been trending positive on Saturday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Cynata Therapeutics earned a media sentiment score of 2.6 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term. View News Stories for Cynata Therapeutics.

Who are some of Cynata Therapeutics' key competitors?

What other stocks do shareholders of Cynata Therapeutics own?

Who are Cynata Therapeutics' key executives?

Cynata Therapeutics' management team includes the folowing people:
  • Dr. Ross Alexander MacDonald Ph.D., MD, CEO & Exec. Director (Age 61)
  • Mr. Peter G. Webse B.Bus, FGIA, FCIS, FCPA, MAICD, Company Sec. & Non-Exec. Director (Age 56)
  • Dr. Kilian Kelly, VP of Product Devel.

How do I buy shares of Cynata Therapeutics?

Shares of CYYNF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cynata Therapeutics' stock price today?

One share of CYYNF stock can currently be purchased for approximately $0.72.

How big of a company is Cynata Therapeutics?

Cynata Therapeutics has a market capitalization of $65.39 million. View Additional Information About Cynata Therapeutics.

MarketBeat Community Rating for Cynata Therapeutics (OTCMKTS CYYNF)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  43 (Vote Outperform)
Underperform Votes:  44 (Vote Underperform)
Total Votes:  87
MarketBeat's community ratings are surveys of what our community members think about Cynata Therapeutics and other stocks. Vote "Outperform" if you believe CYYNF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYYNF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Featured Article: Neutral Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel